Clinical Trial

Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries

Study acronym: GUEST
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to evaluate the performance of UCH-L1 and GFAP combined in patients with a mild traumatic brain injury. The main question : • Does the combination of UCH-L1 and GFAP can exclude brain injuries detected with CT scan in the first twelve hours after a mild traumatic brain injury? Participants will do the exams planed in routine care and : * during the expected blood sampling an additional blood sample will be done, * seven days after the discharge a call will be done by the investigator.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-30; most recent amendment 2025-02-17.
Status change: Not Yet Recruiting → Recruiting 2025-02-17
Trial Details
NCT Number NCT05885529
Lead Sponsor Centre Hospitalier Princesse Grace
Collaborators: BioMérieux, Assistance Publique - Hôpitaux de Paris, University Hospital, Clermont-Ferrand, Hospices Civils de Lyon, Poitiers University Hospital, University Hospital, Angers, Centre Hospitalier Universitaire de Nīmes, Centre Hospitalier Universitaire de Nice, Nantes University Hospital, University Hospital, Montpellier, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, Fondation Hôpital Saint-Joseph, CHU de Tours
Conditions Traumatic Brain Injury
Enrollment 1,500 participants
Start Date 2024-04-19
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-19